CTI opens in Singapore with further expansion in Asia planned

30-Jan-2018 - Last updated on 30-Jan-2018 at 16:16 GMT

(Image: Getty/KCHL)

CTI Clinical Trial and Consulting Services (CTI) has opened a new office in Singapore – a location that will enable the CRO to attract and retain talent as it continues expansion in Asia.

The offices will operate as a wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Singapore Pte. Ltd.

The contract research organization (CRO) has opened more than a dozen offices over the past few years, including new offices in Taipei, Taiwan and Tokyo, Japan in June of 2017.

Pat Earley, vice president, International, CTI, told us the company chose to expand into Singapore because “it is a critically important location for cutting-edge, innovative research including cell and gene therapy which CTI specializes in.”

“The leading academic centers and regulatory authorities have displayed a willingness to develop very open partnerships with pharmaceutical companies, biotechnology companies, and CROs, making Singapore a very desirable county for us to do business in,” he said.

The specific office location was chosen due to its proximity to the Singapore business district and access to medical centers and transportation.

“Its central location will help us attract and retain a qualified workforce as we expand in the area,” added Earley.

According to the company, additional expansions are planned in Asia over the next 12 to 18 months.

The expansion news come on the heels of CTI’s acquisition of Eurotrials in December – a deal that created “one of the 20 largest CROs in the world,” Timothy J. Schroeder, CTI founder and CEO said at the time.